Journal of drugs in dermatology : JDD · 2025
Comparative Efficacy of Deucravacitinib and Adalimumab for Scalp Psoriasis: An Indirect Treatment Comparison.
СтатьяСравнительное исследованиеОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Vardhaman, Hetzel Alexa, Park Sang Hee, Hogan Malcolm, Wu Ying, Fillbrunn Mirko, Patterson-Lomba Oscar, Swallow Elyse, Bagel Jerry
Аннотация
BACKGROUND: Plaque psoriasis of the scalp, a common psoriasis location, remains difficult to manage. The comparative efficacy of newer oral agents, such as deucravacitinib, versus traditional first-generation biologics has not been characterized in the treatment of scalp psoriasis. This study indirectly compared the long-term efficacy of deucravacitinib versus that of adalimumab for the treatment of scalp psoriasis.
METHODS: A literature review identified trial publications reporting long-term efficacy (≥48 weeks) of adalimumab in patients with scalp psoriasis. Based on a feasibility assessment, summary-level adalimumab data (VOYAGE 1 trial [NCT02207231]) were deemed suitable for comparison to patient-level deucravacitinib data (POETYK PSO-1 trial [NCT03624127]). Unadjusted analyses and adjusted analyses using an unanchored matching-adjusted indirect comparison (MAIC) approach were used to describe and compare baseline characteristics and efficacy outcomes in terms of rates of achievement of clear or almost clear scalp psoriasis (scalp-specific Physician Global Assessment score of 0/1 [ss-PGA 0/1]) at weeks 16, 24, and 48.
RESULTS: Cross-trial differences were observed in age, race, severe scalp psoriasis, and quality of life scores. A larger percentage of patients achieved ss-PGA 0/1 at week 48 with deucravacitinib (unadjusted: 76.7%; adjusted: 73.0%) versus adalimumab (60.5%). Similarly, a larger percentage of patients achieved ss-PGA 0/1 at weeks 16 and 24 with deucravacitinib versus adalimumab.
CONCLUSIONS: In this study, treatment with deucravacitinib was effective in treating scalp psoriasis and, when compared with adalimumab, was also associated with a larger percentage of patients achieving ss-PGA 0/1 over 48 weeks.
METHODS: A literature review identified trial publications reporting long-term efficacy (≥48 weeks) of adalimumab in patients with scalp psoriasis. Based on a feasibility assessment, summary-level adalimumab data (VOYAGE 1 trial [NCT02207231]) were deemed suitable for comparison to patient-level deucravacitinib data (POETYK PSO-1 trial [NCT03624127]). Unadjusted analyses and adjusted analyses using an unanchored matching-adjusted indirect comparison (MAIC) approach were used to describe and compare baseline characteristics and efficacy outcomes in terms of rates of achievement of clear or almost clear scalp psoriasis (scalp-specific Physician Global Assessment score of 0/1 [ss-PGA 0/1]) at weeks 16, 24, and 48.
RESULTS: Cross-trial differences were observed in age, race, severe scalp psoriasis, and quality of life scores. A larger percentage of patients achieved ss-PGA 0/1 at week 48 with deucravacitinib (unadjusted: 76.7%; adjusted: 73.0%) versus adalimumab (60.5%). Similarly, a larger percentage of patients achieved ss-PGA 0/1 at weeks 16 and 24 with deucravacitinib versus adalimumab.
CONCLUSIONS: In this study, treatment with deucravacitinib was effective in treating scalp psoriasis and, when compared with adalimumab, was also associated with a larger percentage of patients achieving ss-PGA 0/1 over 48 weeks.